Eli Lilly has been granted patents on baricitinib in over 50 countries. In most countries these patents won't expire until 2029. It is worth noting that certain countries may have laws allowing the extension of market exclusivity beyond the patent terms. For instance, Eli Lilly has secured a patent term extension in Russia until 2033. Also, countries that are member states of the European Patent Office (EPO) may have granted a Supplementary Protection Certificate (SPC) to the medicine extending the exclusivity beyond 2029.